1. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02477800 (2020).
2. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02484547 (2020).
3. US National Library of Medicine. ClincialTrials.gov https://clinicaltrials.gov/ct2/show/NCT01677572 (2020).
4. Biogen. Biogen and Eisai to Discontinue Phase 3 ENGAGE and EMERGE Trials of aducanumab in Alzheimer’s disease. Investors.biogen.com https://investors.biogen.com/news-releases/news-release-details/biogen-and-eisai-discontinue-phase-3-engage-and-emerge-trials (2019).
5. Food and Drug Administration. November 6, 2020 BLA 761178: Peripheral and Central Nervous System Drugs Advisory Committee Meeting. fda.gov https://www.fda.gov/media/143505/download (2020).